rutin and Arteriosclerosis

In a clinically controlled double-blind study it was demonstrated that tri-(hydroxyethyl)-rutin is not capable of significantly improving blood viscosity or one of its constituent factors. On the basis of data from 58 patients, none of whom was under 43 years old, it was possible to show that the substance tested has no favorable influence on plasma viscosity, erythrocyte deformability and aggregation, or on the concentration of plasma proteins which promote aggregation. Thus, in the very group of patients for whom an improvement in blood flow properties by means of oral administration of tri-(hydroxyethyl)rutin had been hoped for, no therapeutic effect could be demonstrated.

Topics: Adult; Anticoagulants; Arteriosclerosis; Blood Proteins; Blood Viscosity; Clinical Trials as Topic; Diabetic Retinopathy; Double-Blind Method; Erythrocyte Aggregation; Erythrocyte Deformability; Erythrocytes; Female; Humans; Hydroxyethylrutoside; Male; Retinal Diseases; Rutin

To evaluate in a group of seriously diseased patients with nonreconstructable chronic critical leg ischemia (CLI), treated by a combination of i.v. hydroxyethylrutosides (HR)* and oral anticoagulation (AC) by warfarin, the short-term effects on the cutaneous microvascular blood perfusion of the soles of feet and especially the long-term clinical outcome in terms of amputation and death.. A retrospective comparison between two groups of patients, HR + AC and a comparable reference group, fulfilling the same inclusion and exclusion criteria corresponding to the definition of CLI according to the Second European Consensus Document (1991). Clinical follow-up in both groups was made after 1, 3, 6, 12, and 24 months.. Patients were examined at university departments of clinical physiology with special interest in peripheral vascular disease, in cooperation with colleagues at university departments of surgery, internal medicine and dermatology of Karolinska Hospital, Södersjukhuset and Huddinge Hospital.. A total of seventy patients with CLI according to the definition of the Second European Consensus Document, 1991, ie, besides severe rest pain or ischemic lesions also a toe blood pressure < 30 mg Hg. Group with HR + anticoagulation (AC): 42 patients (19 diabetics, 23 nondiabetics). Reference group: 28 patients (18 diabetics, 10 nondiabetics). For distribution of age and toe blood pressure at baseline, see Table I.. Therapy group: besides ordinary standard therapy, daily HR infusions for a mean period of 3.6 weeks + oral anticoagulation continued to the end of the study at 24 months. A comparable reference group on the same basic therapy but without the combination HR + AC. PARAMETERS IN EVALUATION: Short-term parameters: clinical data, skin temperature, and fluorescein imaging. Long-term outcome: amputation or death.. Short-term and long-term results with HR + AC indicated that patients with severe CLI and very poor prognosis benefited in terms of survival and limb salvage from initial therapy with HR infusion combined with long-term oral anticoagulation. Results of this combined treatment seem at least comparable with those with i.v. prostacyclin analogies.

Topics: Administration, Oral; Aged; Amputation, Surgical; Anticoagulants; Arteriosclerosis; Blood Pressure; Cardiovascular Agents; Contrast Media; Diabetic Angiopathies; Drug Therapy, Combination; Fluorescein; Follow-Up Studies; Foot; Humans; Hydroxyethylrutoside; Infusions, Intravenous; Ischemia; Leg; Longitudinal Studies; Microcirculation; Prognosis; Retrospective Studies; Skin Temperature; Survival Rate; Treatment Outcome; Warfarin

Atherosclerosis and its clinical manifestations are still one of the most important civilization problems. New questions arise: is it really an inevitable process? Are there any rational methods to prevent the development of atherosclerotic changes or to facilitate its regression? The aim of the work was to evaluate the influence of bioflavonoids extracted from milk thistle (Sylibum marianum L), troxerutin (O-(beta-hydroxy-ethyl)-ruozid and lecithin, administered together and as a single therapy, on the experimental atherosclerosis development in rabbits. Sixty male mixed-breed rabbits were randomly assigned to 6 equal groups: I--control, II--fed on fat-rich diet (FR/DB), III--fed on FR-diet and sylimaryn concentrate (S), IV--animals fed on FR-diet and troxerutin (T), V--rabbits fed on FR-diet and soya bean lecithin (L), VI--animals fed on FR-diet and sylimaryn-phospholipid complex (SF). The whole experiment lasted 12 weeks. Following tests have been performed: electrocardiographic, biochemical, pathomorphological (including macroscopic and microscopic evaluations of aorta). Biochemical analysis included: cholesterol concentration (total, low density lipoprotein fraction cholesterol and high density fraction cholesterol), triglycerides, b-lipoproteins, phospholipids, fibrinogen, trace elements (calcium, magnesium, zinc and copper) and dimalonic aldehyde concentration. Concentrations of ascorbyl free radical, total cholesterol, triglycerides, P-450 cytochrome and phospholipids in liver have been estimated. Evident normalization of lipid metabolism and inhibition of atherosclerotic changes have been observed in the group of animals fed on SF complex. Concentrations of total cholesterol, LDL-cholesterol fraction, phospholipids and triglycerides decreased in serum. Decrease of serum dimalonic aldehyde was followed by increase of ascorbyl free radicals concentration in liver. Significant increase of serum zinc has been also noted, which exceeded values observed in control group. Concentration of P-450 cytochrome increased in liver microsomes. Sylimaryn and lecithin showed less anti-atherosclerotic activity, and troxerutin displayed the least anti-atherosclerotic activity (Tab. 1-2, Fig. 1-2). On the basis of the achieved results the following conclusions were drawn: 1) Sylimaryn and lecithin have anti-atherosclerotic activity in rabbits. 2) Sylimaryn-phospholipid complex shows the strongest anti-atherosclerotic activity. 3) The achieved results allow us to und

Topics: Administration, Oral; Animals; Arteriosclerosis; Cholesterol; Cholesterol, LDL; Cytochrome P-450 Enzyme System; Drug Combinations; Flavonoids; Free Radicals; Hydroxyethylrutoside; Liver; Male; Microsomes; Phosphatidylcholines; Phospholipids; Rabbits; Random Allocation; Silymarin; Triglycerides; Zinc

Four patients with bilateral arterial insufficiency were treated with i.v. hydroxyethylrutoside for three days (1.5 grs twice a day). All patients experienced relief of symptoms. By continuous registration of subcutaneous nutritional blood flow in the forefoot (by 133Xenon clearance technique) a significant increase in nutritional blood flow of 33% on the average during the second and third hour after medication could be demonstrated. The drug seems to be of use in treating subacute occlusions and thrombosis of arteries in the lower extremity.

Topics: Aged; Arteriosclerosis; Blood Pressure; Female; Foot; Humans; Hydroxyethylrutoside; Intermittent Claudication; Male; Middle Aged; Regional Blood Flow; Rutin; Skin; Time Factors

Topics: Adult; Aged; Anticoagulants; Arteriosclerosis; Humans; Hydroxyethylrutoside; Middle Aged; Platelet Aggregation; Rutin

Topics: Adult; Aged; Arterial Occlusive Diseases; Arteriosclerosis; Blood Coagulation; Female; Humans; Hydroxyethylrutoside; Iodine Radioisotopes; Leg; Male; Microcirculation; Middle Aged; Platelet Aggregation; Rutin